Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

This study has been completed.
H. Lundbeck A/S
Information provided by:
University of Southern Denmark Identifier:
First received: June 3, 2008
Last updated: September 9, 2008
Last verified: September 2008

Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours.

It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

Condition Intervention Phase
Drug: escitalopram and tramadol
Drug: placebo
Drug: placebo and tramadol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by University of Southern Denmark:

Primary Outcome Measures:
  • AUC of (+)-M1 metabolite of tramadol [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Dynamic pupillometry [ Time Frame: 24 hours ]

Enrollment: 15
Study Start Date: February 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Escitalopram - tramadol
Drug: escitalopram and tramadol
10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
Other Names:
  • Lexapro
  • Ultram
Experimental: B
Placebo - tramadol
Drug: placebo and tramadol
9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
Other Names:
  • placebo
  • Ultram
Experimental: C
placebo - placebo
Drug: placebo
placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  • Age: 18 - 45 years
  • CYP2D6 phenotyped as extensive metabolizer
  • CYP2C19 phenotyped as extensive metabolizer

Exclusion Criteria:

  • Alcohol or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00692263

Institute of Public Health, Clinical Pharmacology, University of Southern Denmark
Odense, Denmark, DK-5000
Sponsors and Collaborators
University of Southern Denmark
H. Lundbeck A/S
Study Chair: Kim Brosen, MD, D.Sc Institute of Public Healht, Clinical Pharmacology, University of Southern Denmark
  More Information

Responsible Party: Professor, M.D. Kim Brosen, Institute of Pyblic Health, Clinical Pharmacology, University of Soutern Denmark Identifier: NCT00692263     History of Changes
Other Study ID Numbers: AKF-372
EudraCT: 2007-004470-10
Study First Received: June 3, 2008
Last Updated: September 9, 2008

Keywords provided by University of Southern Denmark:
Healthy subjects

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on May 23, 2017